Know Cancer

or
forgot password


Phase 2
18 Years
60 Years
Open (Enrolling)
Both
Hodgkin Lymphoma

Thank you

Trial Information


Inclusion Criteria:



- Histologically proven classical Hodgkin lymphoma

- First diagnosis, no previous treatment, age: 18-60 years

- Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV
disease

Exclusion Criteria:

- Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL)

- Previous malignancy

- Prior chemotherapy or radiation

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response rate (RR) after six cycles of chemotherapy

Outcome Time Frame:

18 weeks

Safety Issue:

No

Principal Investigator

Peter Borchmann, Prof.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Cologne, German Hodgkin Study Group

Authority:

Germany: Paul-Ehrlich-Institut

Study ID:

Targeted BEACOPP

NCT ID:

NCT01569204

Start Date:

October 2012

Completion Date:

December 2015

Related Keywords:

  • Hodgkin Lymphoma
  • Hodgkin Disease
  • Lymphoma

Name

Location